MAPT and in situ carcinoma: Intrathecal synthesis of anti-tau antibodies was significantly higher in all MS clinical forms than in the control group (CIS vs. controls: p<0.01; RR-rMS vs. controls: p<0.005; RR-aMS vs. controls: p<0.05; SPMS vs. controls: p<0.005), but a large overlap among different groups was observed.